Avenue Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OID
Fortress Biotech, Inc. has increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.4% following an annual equity grant.
OID
SCHEDULE 13D/A: Fortress Biotech Solidifies Control and Equity Stake in Avenue Therapeutics with Amended 13D Filing
Fortress Biotech, Inc. has filed an Amendment No. 7 to its Schedule 13D, updating its beneficial ownership in Avenue Therapeutics, Inc. to 10.3% and detailing its continued voting majority through Class A preferred stock and ongoing equity grants.
OID
SCHEDULE 13D/A: Fortress Biotech Increases Stake in Avenue Therapeutics, Maintains Voting Majority Through Preferred Stock
Fortress Biotech, Inc. has increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.8% through equity grants, solidifying its control via Class A preferred stock.